Picture of a calendar. Link to course schedule

View courses by topic or week

Picture of participants from 2019. link to registration information

Find information on pricing and deadlines

Link to Frequently Asked Questions page

Get answers to all of your questions

Advances in the Biology and Management of COVID-19

Image of coronavirus moleculeAdvances in the Biology and Management of COVID-19 | May 30 – June 1, 2022

COURSE FORMAT

Online only. Course will be live approximately 9:00am-1:00pm (Montreal time) each day May 30 – June 1, 2022. Live content will be recorded.

DESCRIPTION

This course will introduce the up-to-date key concepts in the biology, prevention, and management in the efforts to mitigate and contain the COVID-19 pandemic. Students will learn about the epidemiology and transmission of SARS-CoV-2 which has contributed to its dissemination worldwide. Topics will revolve around understanding the virus’ biology, novel diagnostic approaches, its impact on special populations, up-to-date therapeutic approaches as well as preventative strategies using vaccines and other public health measures.

DIRECTORS

Chen Liang, PhD
Professor, Department of Medicine, McGill University
Director, McGill Centre for Viral Diseases

Gerasimos J. Zaharatos, MD
Associate Professor, Department of Medicine, McGill University
Chief, Division of Medical Microbiology, OptiLab Montreal, McGill University Health Centre
Associate Chief, Division of Infectious Diseases, Jewish General Hospital

PREVIOUS COURSE FACULTY

Brett Thombs – McGill University
Brian Ward – McGill University
Emily Jenkins - University of Saskatchewan
Emily McDonald – McGill University
Giorgia Sulis – McGill University
Isabelle Malhame – McGill University
Jesse Papenburg – McGill University
Leighanne Parkes – McGill University
Nadine Kronfli – McGill University
Tim Evans – McGill University

Faculty are still being confirmed and there may be changes to the above list.

CONTENT

In order to contain the COVID-19 pandemic, we need to increase diagnostic capacity and implement public health mitigation strategies. Effective measures will focus on the widespread administration of a safe and effective vaccine, as well as therapeutic approaches for both in and outpatients. There is plenty of evidence that COVID-19 has had a disproportionate impact on certain populations (e.g. people of certain socioeconomic status and ethnic origins) and understandings these differences will be paramount in containing this pandemic. This session of leading international experts will:

  • Review the biology and transmission of SARS-CoV-2
  • Discuss and highlight the epidemiology of the COVID-19 pandemic
  • Present novel diagnostic strategies for SARS-CoV-2
  • Discuss and debate the best therapeutic interventions for the management of inpatient and outpatients with COVID-19
  • Highlight key differences in the manifestations of COVID-19 in special populations (including children, pregnant women, and disenfranchised individuals)
  • Explore the role of technology in the management of COVID-19
  • Present and debate the optimal vaccination strategy against COVID-19
  • Understand and mitigate the impact of COVID-19 on mental health

OBJECTIVES

By the end of the course, participants will be able to:

  • Understand the basic properties of SARS-CoV-2 in the context of its biology, pathogenesis, transmission and epidemiology.
  • Review various approaches to the management of inpatient and outpatients with COVID-19
  • Summarize current evidence on the diagnosis of SARS-CoV-2 infection, and give examples of specific use cases
  • Describe optimal public health mitigation strategies, including vaccination, against the COVID-19 pandemic, and highlight current gaps to be addressed in the future
  • Present the impact of COVID-19 on social life, mental health, and at-risk populations

TARGET AUDIENCE

  • Clinicians and nurses
  • Undergraduate students, graduate students, medical school students, postdoctoral fellows,
  • Researchers and academics involved in SARS-CoV-2 research
  • Funding agencies
  • Product development partnerships
  • Policy makers and public health implementers
  • Community advocates and civil society

ENROLMENT

Unlimited

 

Tags: 
Back to top